159 related articles for article (PubMed ID: 34998467)
1. SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display.
Ehling RA; Weber CR; Mason DM; Friedensohn S; Wagner B; Bieberich F; Kapetanovic E; Vazquez-Lombardi R; Di Roberto RB; Hong KL; Wagner C; Pataia M; Overath MD; Sheward DJ; Murrell B; Yermanos A; Cuny AP; Savic M; Rudolf F; Reddy ST
Cell Rep; 2022 Jan; 38(3):110242. PubMed ID: 34998467
[TBL] [Abstract][Full Text] [Related]
2. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
4. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
[TBL] [Abstract][Full Text] [Related]
5. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
6. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
7. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouse
Yang X; Chi H; Wu M; Wang Z; Lang Q; Han Q; Wang X; Liu X; Li Y; Wang X; Huang N; Bi J; Liang H; Gao Y; Zhao Y; Feng N; Yang S; Wang T; Xia X; Ge L
Front Immunol; 2022; 13():992787. PubMed ID: 36211410
[TBL] [Abstract][Full Text] [Related]
9. Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
Thakur N; Conceicao C; Isaacs A; Human S; Modhiran N; McLean RK; Pedrera M; Tan TK; Rijal P; Townsend A; Taylor G; Young PR; Watterson D; Chappell KJ; Graham SP; Bailey D
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33054904
[TBL] [Abstract][Full Text] [Related]
10. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
Cao Y; Su B; Guo X; Sun W; Deng Y; Bao L; Zhu Q; Zhang X; Zheng Y; Geng C; Chai X; He R; Li X; Lv Q; Zhu H; Deng W; Xu Y; Wang Y; Qiao L; Tan Y; Song L; Wang G; Du X; Gao N; Liu J; Xiao J; Su XD; Du Z; Feng Y; Qin C; Qin C; Jin R; Xie XS
Cell; 2020 Jul; 182(1):73-84.e16. PubMed ID: 32425270
[TBL] [Abstract][Full Text] [Related]
11. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
13. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.
Vanshylla K; Fan C; Wunsch M; Poopalasingam N; Meijers M; Kreer C; Kleipass F; Ruchnewitz D; Ercanoglu MS; Gruell H; Münn F; Pohl K; Janicki H; Nolden T; Bartl S; Stein SC; Augustin M; Dewald F; Gieselmann L; Schommers P; Schulz TF; Sander LE; Koch M; Łuksza M; Lässig M; Bjorkman PJ; Klein F
Cell Host Microbe; 2022 Jan; 30(1):69-82.e10. PubMed ID: 34973165
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
16. Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq.
He B; Liu S; Wang Y; Xu M; Cai W; Liu J; Bai W; Ye S; Ma Y; Hu H; Meng H; Sun T; Li Y; Luo H; Shi M; Du X; Zhao W; Chen S; Yang J; Zhu H; Jie Y; Yang Y; Guo D; Wang Q; Liu Y; Yan H; Wang M; Chen YQ
Signal Transduct Target Ther; 2021 May; 6(1):195. PubMed ID: 34001847
[TBL] [Abstract][Full Text] [Related]
17. Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses.
Bullen G; Galson JD; Hall G; Villar P; Moreels L; Ledsgaard L; Mattiuzzo G; Bentley EM; Masters EW; Tang D; Millett S; Tongue D; Brown R; Diamantopoulos I; Parthiban K; Tebbutt C; Leah R; Chaitanya K; Ergueta-Carballo S; Pazeraitis D; Surade SB; Ashiru O; Crippa L; Cowan R; Bowler MW; Campbell JI; Lee WJ; Carr MD; Matthews D; Pfeffer P; Hufton SE; Sawmynaden K; Osbourn J; McCafferty J; Karatt-Vellatt A
Front Immunol; 2021; 12():678570. PubMed ID: 34211469
[TBL] [Abstract][Full Text] [Related]
18. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.
Noval MG; Kaczmarek ME; Koide A; Rodriguez-Rodriguez BA; Louie P; Tada T; Hattori T; Panchenko T; Romero LA; Teng KW; Bazley A; de Vries M; Samanovic MI; Weiser JN; Aifantis I; Cangiarella J; Mulligan MJ; Desvignes L; Dittmann M; Landau NR; Aguero-Rosenfeld M; Koide S; Stapleford KA
Sci Rep; 2021 Mar; 11(1):5538. PubMed ID: 33692390
[TBL] [Abstract][Full Text] [Related]
19. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
20. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
